News

The new advisory is informed by currently-understood effect of authorized vaccines against circulating SARS-CoV-2—which show benefit nonetheless.

According to the federal agency, anaphylaxis from mRNA COVID-19 vaccinations is a rare event.

Mediterranean region imposes partial lockdown following a surge in cases.

A John Hopkins expert and major study leader details the evolving epidemiology of the virus.

Investigators at Cedars-Sinai Medical Center identified a variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), called CAL.20C, which accounted for about 44% of samples in Southern California in January.

HIV-associated wasting remains common complication despite treatment with antiretroviral therapy.

Immune memory is the basis for durable protective immunity after infections or vaccinations.

The news comes on the same day as new data showing the vaccine's efficacy as a single-dose prophylactic, as well as the company's application for eased storage standards for US supplies.

The session was part of the COVID-19 Real Time Learning Network.

The biweekly webinars hosted by renowned health care thought leaders provide resources to improve patient outcomes during COVID-19. Here's a recap of the first 5 discussions.

The interval between doses can be safely extended to 3 months given the protection a single dose offers.

Ruth Coker Burks’ new book, All the Young Men, chronicles her years at the bedside of victims.

An Israeli study finds it had an 85% effect in lowering disease 2 to 4 weeks after administration of the initial vaccination.

Children are about half as susceptible as adults to contracting COVID-19, according to new research from Israel.

Findings may be valuable in situations where there is a limited testing capacity.

Findings indicate potential ways to identify individuals at higher or lower risk.

HIV testing and initiation of antiretroviral therapy (ART) fell in South Africa during the national lockdown in response to the coronavirus disease 2019 (COVID-19) pandemic, a new study shows.

In lab studies, neutralizing antibody activity was reported but there was a reduction shown in both m-RNA vaccines.

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.

The government-funded trial will seek to interpret the virus' transmissibility and infection, in order to inform vaccination and treatment strategies.

Study pinpoints the protein RIPK1 as a promising target for SARS-CoV-2 treatment.

The study was the first randomized clinical trial using the therapy to treat POTS.

As more people contract and recover from COVID-19, a small percentage suffer from lingering or even new symptoms for months. Post COVID clinics aim to address the causes and provide relief.

This new variant, B.1.525, was discovered in both the United Kingdom and Nigeria, and is now in 11 other countries including the United States.

Evaluating the impact of the SARS-CoV-2 virus on hospitalized patients.

The PCR diagnostic joins the company’s host of other SARS-CoV-2 research solutions.